



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 239/94, A61K 31/505	A1	(11) International Publication Number: WO 99/55683 (43) International Publication Date: 4 November 1999 (04.11.99)
<p>(21) International Application Number: PCT/IB99/00612</p> <p>(22) International Filing Date: 8 April 1999 (08.04.99)</p> <p>(30) Priority Data: 60/083,441 29 April 1998 (29.04.98) US</p> <p>(71) Applicant (for all designated States except US): PFIZER PRODUCTS INC. [US/US]; Eastern Point Road, Groton, CT 06340 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): ALLEN, Douglas, John, Meldrum [US/US]; 549 Ocean Avenue, New London, CT 06320 (US). NORRIS, Timothy [GB/US]; 27 Friar Tuck Drive, Gales Ferry, CT 06335 (US). RAGGON, Jeffrey, William [US/US]; 48 Teeecomwas Drive, Uncasville, CT 06382 (US). SANTAFIANOS, Dinos, Paul [GB/US]; 93 Gerald Drive, Manchester, CT 06040 (US). SHANKER, Ravi, Mysore [IN/US]; Apartment #816, 600 Meridian Street Extension, Groton, CT 06340 (US).</p> <p>(74) Agents: SPIEGEL, Allen, J. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>
<p>(54) Title: N-(3-ETHYNYLPHENYLAMINO)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMINE MESYLATE ANHYDRATE AND MONOHYDRATE</p> <p>(57) Abstract</p> <p>The present invention relates to the anhydrous and hydrate forms of N- (3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate. The invention also relates to pharmaceutical compositions containing N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate and to methods of treating hyperproliferative disorders, such as cancer, by administering N- (3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

5 N-(3-ETHYNYLPHENYLAMINO)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMINE
MESYLATE ANHYDRATE AND MONOHYDRATE

Background of the Invention

The present invention relates to novel N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrous and hydrate forms. These compounds are useful in the treatment of hyperproliferative disorders, such as cancers, in mammals.

United States patent application number 08/653,786, filed May 28, 1996, which is incorporated herein by reference in its entirety, refers to [6,7-bis(2-methoxyethoxy)-quinazolin-4-yl]-(3-ethynylphenyl)amine hydrochloride which, the patent application discloses, is an inhibitor of the erbB family of oncogenic and protooncogenic protein tyrosine kinases, such as epidermal growth factor receptor (EGFR), and is therefore useful for the treatment of proliferative disorders, such as cancers, in humans. The mesylate compounds of the present invention are similarly useful for the treatment of proliferative disorders, but they also possess certain advantages over the foregoing hydrochloride compound. One advantage is that the mesylate compounds of the present invention are more soluble in aqueous compositions than the above hydrochloride compound, and thus the mesylate compounds of the present invention are easily delivered according to parenteral methods of administration.

Summary of the Invention

The present invention relates to the anhydrous and hydrate forms of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate.

25 A specific embodiment of the present invention comprises the anhydrous form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate. In particular, the anhydrous form includes polymorphs A, B, and C, having X-ray powder diffraction patterns as described below.

Another specific embodiment of the present invention comprises N-(3-ethynylphenyl)-
30 6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate monohydrate.

The invention also relates to a pharmaceutical composition for the treatment of a hyperproliferative disorder in a mammal which comprises a therapeutically effective amount of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate, and a pharmaceutically acceptable carrier. In one embodiment, said pharmaceutical composition is for the treatment of cancer such as brain, lung, squamous cell, bladder, gastric, pancreatic, breast, head, neck, renal (such as kidney), ovarian, prostate, colorectal, oesophageal, gynecological or thyroid cancer. In another embodiment, said pharmaceutical composition is for the treatment of a non-cancerous hyperproliferative disorder such as benign hyperplasia of the skin (e.g., psoriasis) or prostate (e.g., benign prostatic hypertrophy (BPH)).

40 The invention also relates to a pharmaceutical composition for the treatment of pancreatitis or kidney disease (including proliferative glomerulonephritis and diabetes-induced renal disease) in a mammal which comprises a therapeutically effective amount of N-(3-

5 ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate and a pharmaceutically acceptable carrier.

The invention also relates to a pharmaceutical composition for the prevention of blastocyte implantation in a mammal which comprises a therapeutically effective amount of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate and a pharmaceutically acceptable carrier.

10 The invention also relates to a pharmaceutical composition for treating a disease related to vasculogenesis or angiogenesis in a mammal which comprises a therapeutically effective amount of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate and a pharmaceutically acceptable carrier. In one embodiment, said pharmaceutical composition is for treating a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, atherosclerosis, skin diseases such as psoriasis, excema, and scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma, Kaposi's sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer.

20 The invention also relates to a method of treating a hyperproliferative disorder in a mammal which comprises administering to said mammal a therapeutically effective amount of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate. In one embodiment, said method relates to the treatment of cancer such as brain, squamous cell, bladder, gastric, pancreatic, breast, head, neck, oesophageal, prostate, colorectal, lung, renal (such as kidney), ovarian, gynecological or thyroid cancer. In another embodiment, said method relates to the treatment of a non-cancerous hyperproliferative disorder such as benign hyperplasia of the skin (e.g., psoriasis) or prostate (e.g., benign prostatic hypertrophy (BPH)).

30 The invention also relates to a method for the treatment of a hyperproliferative disorder in a mammal which comprises administering to said mammal a therapeutically effective amount of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate in combination with an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, and anti-androgens.

35 Patients that can be treated with N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate according to the methods of this invention include, for example, patients that have been diagnosed as having psoriasis, BPH, lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head and neck, cutaneous or intraocular melanoma, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, gynecologic tumors (e.g., uterine sarcomas, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina or carcinoma of the vulva), Hodgkin's disease, cancer of the esophagus, cancer of the small


- 5 intestine, cancer of the endocrine system (e.g., cancer of the thyroid, parathyroid or adrenal glands), sarcomas of soft tissues, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, solid tumors of childhood, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter (e.g., renal cell carcinoma, carcinoma of the renal pelvis), or neoplasms of the central nervous system (e.g., primary CNS lymphoma, spinal axis tumors,
- 10 brain stem gliomas or pituitary adenomas).

Detailed Description of the Invention

N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate has been found to exist in three distinct anhydrous polymorphic forms A, B and C and also as a monohydrate. The relationship of these forms is illustrated in the Scheme below.

15

Scheme



- N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride may be prepared as described in United States patent application number 08/653,786, filed May 28, 1996, referred to above. N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate monohydrate may be prepared by mixing N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride in ethyl acetate and water, warming the mixture to a temperature of about 60-70°C, adding sodium hydroxide to adjust the pH to within a range of about 10-11, separating the organic ethyl acetate phase, and then adding methanesulfonic acid to the organic phase to provide the mesylate monohydrate.
- 25

- The anhydrous mesylate characterized as polymorph A may be prepared by mixing the mesylate monohydrate, prepared as described above, in ethyl acetate or isopropanol, heating the mixture to reflux for about 1 day, and then cooling to ambient temperature to allow crystallization.
- 30

5 The anhydrous mesylate characterized as polymorph B may be prepared by mixing the mesylate monohydrate in isopropanol and heating the mixture to about 45-55°C for a period of about 5 hours. The anhydrous mesylate characterized as polymorph B may also be prepared by mixing N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride in dichloromethane and water, separating the organic phase, mixing isopropanol
10 in the organic phase, adding methanesulfonic acid to the organic phase and then adding seed crystals of the mesylate anhydrate polymorph B to effect crystallization of polymorph B.

The anhydrous mesylate characterized as polymorph C may be prepared by mixing polymorph B, prepared as described above, in isopropanol at a temperature of about 60-70°C for a period ranging from 18 hours to about 3 days. The anhydrous mesylate characterized as
15 polymorph C may also be prepared by mixing N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride in ethyl acetate and water, treating the mixture with sodium hydroxide to raise the pH to about 8-9, separating the organic phase, mixing isopropanol in the organic phase, adding methanesulfonic acid to the organic phase, heating the mixture to about 70°C for about 16 hours, and then cooling the mixture to effect crystallization of
20 polymorph C.

Polymorphs A, B and C can be converted into the monohydrate by treatment with water. Each of the mesylate compounds of the present invention is more soluble in aqueous compositions than N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, referred to above. Polymorph C is essentially non-hygroscopic and has
25 resistance to thermal degradation.

The polymorphs A, B and C are characterized by the principal peaks found in the X-ray powder diffraction patterns shown below.

Characteristic Peaks found in X-ray diffraction pattern of Polymorph A

(* strongly absorbing peaks)

Peak No.	1*	2*	3	4	5	6	7	8	9	10
2 q (°) Cu	6.3	7.15	9.8	13.4	13.7	18.05	18.9	19.6	20.0	21.35
d space	14.1	12.3	9.0	6.6	6.4	4.9	4.7	4.5	4.4	4.15
Peak No.	11	12	13	14	15	16	17	18	19	20
2 q (°) Cu	21.8	23.1	26.8							
d space	4.1	3.85	3.3							

5 Characteristic Peaks found in X-ray diffraction pattern of Polymorph B
 (* strongly absorbing peaks)

Peak No.	1*	2*	3*	4*	5	6	7	8	9	10
2 q (°) Cu	5.4	8.8	13.4	13.7	15.3	15.7	17.4	17.8	18.4	18.8
d space	16.3	10.1	6.6	6.5	5.8	5.65	5.1	5.0	4.8	4.7
Peak No.	11	12	13	14	15	16	17	18	19	20
2 q (°) Cu	19.5	19.85	20.1	21.1	21.8	22.6	24.1	25.2*	25.9*	26.7
d space	4.55	4.5	4.4	4.2	4.1	3.9	3.7	3.5	3.4	3.3
Peak No.	21	22	23	24	25	26	27	28	29	30
2 q (°) Cu	28.3	30.9								
d space	3.1	2.9								

Characteristic Peaks found in X-ray diffraction pattern of Polymorph C
 (* strongly absorbing peaks)

Peak No.	1	2	3	4*	5	6*	7	8	9*	10
2 q (°) Cu	6.0	8.3	10.3	11.5	12.55	13.45	16.0	16.75	17.4	17.9
d space	14.7	10.6	8.6	7.7	7.05	6.6	5.5	5.3	5.1	4.95
Peak No.	11	12	13	14*	15	16*	17	18	19*	20
2 q (°) Cu	18.1	18.65	19.35	20.6	23.0	24.0	24.8	26.75	27.2	36.3
d space	4.9	4.75	4.6	4.3	3.9	3.7	3.6	3.3	3.3	2.5

10

Characteristic Peaks found in X-ray diffraction pattern of Monohydrate
 (* strongly absorbing peak)

Peak No.	1*	2	3	4	5
2 q (°) Cu	5.7	7.0	11.3	20.5	25.1
d space	15.5	12.5	7.8	4.3	3.5

15 The compounds of the present invention are potent inhibitors of the erbB family of
 oncogenic and protooncogenic protein tyrosine kinases such as epidermal growth factor receptor
 (EGFR), *erbB2*, *HER3*, or *HER4* and thus are all adapted to therapeutic use as antiproliferative
 agents (e.g., anticancer) in mammals, particularly in humans. The compounds of the present
 invention are also inhibitors of angiogenesis and/or vasculogenesis. In particular, the
 20 compounds of the present invention are useful in the prevention and treatment of a variety of
 human hyperproliferative disorders such as malignant and benign tumors of the liver, kidney,
 bladder, breast, gastric, ovarian, colorectal, prostate, pancreatic, lung, vulval, thyroid, hepatic
 carcinomas, sarcomas, glioblastomas, head and neck, and other hyperplastic conditions such as

5 benign hyperplasia of the skin (e.g., psoriasis) and benign hyperplasia of the prostate (e.g., BPH). It is expected that a compound of the present invention may possess activity against a range of leukemias and lymphoid malignancies.

The compounds of the present invention may also be useful in the treatment of additional disorders in which aberrant expression ligand/receptor interactions or activation or
10 signalling events related to various protein tyrosine kinases are involved. Such disorders may include those of neuronal, glial, astrocytal, hypothalamic, glandular, macrophagal, epithelial, stromal, or blastocoelic nature in which aberrant function, expression, activation or signalling of the erbB tyrosine kinases are involved. In addition, the compounds of the present invention may have therapeutic utility in inflammatory, angiogenic and immunologic disorders involving both
15 identified and as yet unidentified tyrosine kinases that are inhibited by the compounds of the present invention.

The *in vitro* activity of the compounds of the present invention in inhibiting the receptor tyrosine kinase (and thus subsequent proliferative response, e.g., cancer) may be determined by the following procedure.

20 The activity of the compounds of the present invention, *in vitro*, can be determined by the amount of inhibition of the phosphorylation of an exogenous substrate (e.g., Lys₃ - Gastrin or polyGluTyr (4:1) random copolymer (I. Posner et al., J. Biol. Chem. 267 (29), 20638-47 (1992)) on tyrosine by epidermal growth factor receptor kinase by a test compound relative to a control. Affinity purified, soluble human EGF receptor (96 ng) is obtained according to the procedure in
25 G. N. Gill, W. Weber, Methods in Enzymology 146, 82-88 (1987) from A431 cells (American Type Culture Collection, Rockville, MD) and preincubated in a microfuge tube with EGF (2µg/ml) in phosphorylation buffer + vanadate (PBV: 50 mM HEPES, pH 7.4; 125 mM NaCl; 24 mM MgCl₂; 100 µM sodium orthovanadate), in a total volume of 10 µl, for 20-30 minutes at room temperature. The test compound, dissolved in dimethylsulfoxide (DMSO), is diluted in PBV, and
30 10 µl is mixed with the EGF receptor /EGF mix, and incubated for 10-30 minutes at 30°C. The phosphorylation reaction is initiated by addition of 20 µl ³³P-ATP/ substrate mix (120 µM Lys₃-Gastrin (sequence in single letter code for amino acids, KKKGPWLEEEEEAYGWLDF), 50 mM Hepes pH 7.4, 40 µM ATP, 2 µCi γ-[³³P]-ATP) to the EGFr/EGF mix and incubated for 20 minutes at room temperature. The reaction is stopped by addition of 10 µl stop solution (0.5 M
35 EDTA, pH 8; 2mM ATP) and 6 µl 2N HCl. The tubes are centrifuged at 14,000 RPM, 4°C, for 10 minutes. 35 µl of supernatant from each tube is pipetted onto a 2.5 cm circle of Whatman P81 paper, bulk-washed four times in 5% acetic acid, 1 liter per wash, and then air dried. This results in the binding of substrate to the paper with loss of free ATP on washing. The [³³P] incorporated is measured by liquid scintillation counting. Incorporation in the absence of substrate (e.g., lys₃-gastrin) is subtracted from all values as a background and percent inhibition is calculated relative
40 to controls without test compound present. Such assays, carried out with a range of doses of

- 5 test compounds, allow the determination of an approximate IC_{50} value for the *in vitro* inhibition of EGFR kinase activity.

Other methods for determining the activity of the compounds of the present invention are described in United States patent application number 08/653,786, referred to above.

- 10 Administration of the compounds of the present invention (hereinafter the "active compound(s)") can be effected by any method that enables delivery of the compounds to the site of action. These methods include oral routes, intraduodenal routes, parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion), topical, and rectal administration. Parenteral administration is preferred.

- The amount of the active compound administered will be dependent on the subject
15 being treated, the severity of the disorder or condition, the rate of administration and the judgement of the prescribing physician. However, an effective dosage is in the range of about 0.001 to about 100 mg per kg body weight per day, preferably about 1 to about 35 mg/kg/day, in single or divided doses. For a 70 kg human, this would amount to about 0.05 to about 7 g/day, preferably about 0.2 to about 2.5 g/day. In some instances, dosage levels below the lower limit
20 of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several small doses for administration throughout the day.

- The active compound may be applied as a sole therapy or may involve one or more other anti-tumour substances, for example those selected from, for example, mitotic inhibitors,
25 for example vinblastine; alkylating agents, for example cis-platin, carboplatin and cyclophosphamide; anti-metabolites, for example 5-fluorouracil, cytosine arabinoside and hydroxyurea, or, for example, one of the preferred anti-metabolites disclosed in European Patent Application No. 239362 such as N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic acid; growth factor inhibitors; cell cycle inhibitors;
30 intercalating antibiotics, for example adriamycin and bleomycin; enzymes, for example interferon; and anti-hormones, for example anti-estrogens such as NolvadexTM (tamoxifen) or, for example anti-androgens such as CasodexTM (4'-cyano-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide). Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment.

- 35 The pharmaceutical composition may, for example, be in a form suitable for oral administration as a tablet, capsule, pill, powder, sustained release formulations, solution, suspension, for parenteral injection as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository. The pharmaceutical composition may be in unit dosage forms suitable for single administration of
40 precise dosages. The pharmaceutical composition will include a conventional pharmaceutical

5 carrier or excipient and a compound according to the invention as an active ingredient. In addition, it may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc.

Exemplary parenteral administration forms include solutions or suspensions of active compounds in sterile aqueous solutions, for example, aqueous propylene glycol or dextrose solutions. Such dosage forms can be suitably buffered, if desired.

10 Suitable pharmaceutical carriers include inert diluents or fillers, water and various organic solvents. The pharmaceutical compositions may, if desired, contain additional ingredients such as flavorings, binders, excipients and the like. Thus for oral administration, tablets containing various excipients, such as citric acid may be employed together with various disintegrants such as starch, alginic acid and certain complex silicates and with binding agents
15 such as sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tableting purposes. Solid compositions of a similar type may also be employed in soft and hard filled gelatin capsules. Preferred materials, therefor, include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration
20 the active compound therein may be combined with various sweetening or flavoring agents, coloring matters or dyes and, if desired, emulsifying agents or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin, or combinations thereof.

Methods of preparing various pharmaceutical compositions with a specific amount of active compound are known, or will be apparent, to those skilled in this art. For examples, see
25 Remington's Pharmaceutical Sciences, Mack Publishing Company, Easter, Pa., 15th Edition (1975).

The examples and preparations provided below further illustrate and exemplify the compounds of the present invention and methods of preparing such compounds. It is to be understood that the scope of the present invention is not limited in any way by the scope of the
30 following examples and preparations.

Example 1

Preparation of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate salt monohydrate

The hydrochloride salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-
35 quinazolinamine (12.0g, 27.91 mmol), ethyl acetate (200 mL) and water (50 mL) were mixed together using mechanical agitation and then warmed to 60 - 70°C. The stirred mixture was treated portionwise with 50% aqueous sodium hydroxide (~14 mL) so that the pH of the aqueous phase was in the range 10 - 11. The mixture was allowed to settle and separate into two clear liquid phases. The aqueous phase was removed and the residual clear organic
40 layer was heated to reflux in a Dean and Stark apparatus to azeotropically remove residual water. The volume of the organic layer was reduced by about 60 mL during this procedure. The hot organic solution was stirred and treated slowly with methanesulfonic acid (2.2 mL,

5 33.49 mmol) to give a hazy solution which on cooling to room temperature gave a crystal slurry. The crystal slurry was granulated for 1 hour in the temperature range 0 - 5°C, the crystals were isolated by filtration, washed with cold ethyl acetate (2 x 50 mL) and dried under vacuum at 35°C to give the monohydrate 14.2g, yield 100%, as a white crystalline solid mp 96 - 100°C.

10 The monohydrate is characterized by the powder X-ray diffraction pattern noted above.

Example 2

Preparation of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate salt polymorph A

15 A mixture of the monohydrate product of example 1 above, (15.0g) and ethyl acetate (150 mL) was boiled at reflux in a Dean and Stark apparatus so that water was azeotropically removed over a period of 25 hours. The heat source was removed and the crystal slurry allowed to cool to room temperature and was granulated for 24 hours. The crystalline product was isolated by filtration and dried under vacuum at 38°C to give polymorph A, 14.04g, yield
20 97%, as a pale yellow crystalline solid mp 161 -162°C.

Polymorph A is characterized by the powder X-ray diffraction pattern noted above.

Example 3

Preparation of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate salt polymorph A

25 A mixture of the monohydrate product of example 1 above, (20.0g) and isopropanol (120 mL) was boiled at reflux for a period of 2 hours. The heat source was removed and the crystal slurry allowed to cool to room temperature and was granulated for 1 hour. The crystalline product was isolated by filtration and dried under vacuum at 38°C to give polymorph A, 18.07g, yield 93%, as a pale yellow crystalline solid mp 160 -161°C.

30 Polymorph A is characterized by the powder X-ray diffraction pattern noted above.

Example 4

Preparation of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate salt polymorph B

35 A mixture of the monohydrate product of example 1 above, (10.0g) and isopropanol (100 mL) was stirred mechanically in the temperature range 45 - 55°C for a period of 5 hours. The heat source was removed and while the crystalline slurry was still above ambient temperature the crystalline product was isolated by filtration and dried under vacuum at 47°C to give polymorph B, 9.06g, yield 94%, as a white crystalline solid mp 142 -144°C.

Polymorph B is characterized by the powder X-ray diffraction pattern noted above.

5

Example 5Preparation of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate salt polymorph B

The hydrochloride salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine (30.0g, 69.79 mmol), dichloromethane (1125 mL) and water (300 mL) were mixed together using mechanical agitation and then treated with saturated sodium bicarbonate solution (300 mL). The mixture was allowed to settle and separate into two cloudy liquid phases. The aqueous phase was removed and further extracted with dichloromethane (300 mL). The organic layers were combined and washed with saturated sodium bicarbonate solution (300 mL), separated and dried by treatment with dried magnesium sulfate (50g) and then filtered to give a clear organic layer which was concentrated by evaporation to a volume of about 300 mL. The resultant solution was treated with isopropanol (450 mL) and concentrated by evaporation to 300 mL giving a slurry mixture. The slurry mixture was treated slowly with methanesulfonic acid (4.5 mL, 69.79 mmol) to give a pale yellow solution which on cooling to room temperature gave a gum. Addition of seed crystals of polymorph B as prepared in example 4 eventually resulted in formation of a crystal slurry. The crystal slurry was granulated for 24 hours at ambient temperature overnight, the crystals were isolated by filtration, washed with isopropanol (50 mL) and dried under vacuum at 45°C to give polymorph B, 23.43g, yield 69%, as a white crystalline solid mp 142 -144°C.

Polymorph B is characterized by the powder X-ray diffraction pattern noted above.

25

Example 6Preparation of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate salt polymorph C

A mixture of the polymorph B product of example 4 or 5 above, (10.0g) and isopropanol (100 mL) was stirred mechanically in the temperature range 60 - 63°C for a period of 3 days. The heat source was removed and the crystalline product was isolated by filtration and dried under vacuum at 47°C to give polymorph C, 8.08g, yield 81%, as a white crystalline solid mp 152 -154°C.

Polymorph C is characterized by the powder X-ray diffraction pattern noted above.

Example 7

35

Preparation of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate salt polymorph C

A mixture of the polymorph B product of example 4 or 5 above, (20.0g) and isopropanol (300 mL) was stirred mechanically in the temperature range 65 - 70°C for a period of 22 hours. The conversion time varies, typically being in the range 18 - 24 hours for the conditions indicated. The conversion of polymorph B into polymorph C may be monitored using near-infrared spectroscopy after the method of Norris, Aldridge and Sekulic, *Analyst*, 1997, **122**, 549. In this way a precise conversion time can be determined for each individual

- 5 run. The heat source was removed and the mixture cooled to room temperature and granulated for a period of 1 hour. The crystalline product was isolated by filtration and dried under vacuum at 36°C to give polymorph C, 19.42g, yield 97%, as a white crystalline solid mp 153 -155°C.

Polymorph C is characterized by the powder X-ray diffraction pattern noted above.

10

Example 8

Preparation of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate salt polymorph C

- The hydrochloride salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine (100.0 g, 0.223 mole), ethyl acetate (2000 mL) and water (500 mL) were
15 mixed together using mechanical agitation and then warmed to 40 - 45°C. The stirred mixture was treated portionwise with 50% aqueous sodium hydroxide (40 mL) so that the pH of the aqueous phase was in the range 8 - 9. The mixture was allowed to settle and separate into two clear liquid phases. The aqueous phase was removed and organic phase washed with water (300 mL). The resultant pale yellow organic solution was filtered to obtain a clear
20 solution which was concentrated by distillation at atmospheric pressure to remove 1L of solvent. Isopropanol (2L) was added to the concentrate and a further 1L of solvents were removed by distillation at atmospheric pressure. The resultant concentrate was cooled to 40°C and treated with methanesulfonic acid (15.1 mL, 0.233 mole) and allowed to crystallize. The crystal slurry was warmed to 62°C for 18 hours. Monitoring with near-infrared
25 spectroscopy after the method of Norris, Aldridge and Sekulic, *Analyst*, 1997 ,122, 549, indicated that no conversion to polymorph C had occurred. The temperature was raised to 70°C, after a period of 16 hours, near-infrared monitoring as described indicated the conversion was complete. The heat source was removed and the mixture cooled to 0 - 5°C and granulated for a period of 1 hour. The crystalline product was isolated by filtration,
30 washed with isopropanol (50 mL) and dried under vacuum at 33°C to give polymorph C, 105.63g, yield 93%, as a white crystalline solid mp 153 - 156°C.

Polymorph C is characterized by the powder X-ray diffraction pattern noted above.

5

CLAIMS

1. A compound selected from the anhydrous and hydrate forms of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate.

2. A compound according to claim 1 wherein said compound is an anhydrous form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate.

10

3. A compound according to claim 2 wherein said compound is polymorph A characterized by the following peaks in its X-ray powder diffraction pattern

Peak No.	1	2	3	4	5	6	7	8	9	10
2 q (°) Cu	6.3	7.15	9.8	13.4	13.7	18.05	18.9	19.6	20.0	21.35
d space	14.1	12.3	9.0	6.6	6.4	4.9	4.7	4.5	4.4	4.15
Peak No.	11	12	13	14	15	16	17	18	19	20
2 q (°) Cu	21.8	23.1	26.8							
d space	4.1	3.85	3.3							

4. A compound according to claim 2 wherein said compound is polymorph B characterized by the following peaks in its X-ray powder diffraction pattern

Peak No.	1	2	3	4	5	6	7	8	9	10
2 q (°) Cu	5.4	8.8	13.4	13.7	15.3	15.7	17.4	17.8	18.4	18.8
d space	16.3	10.1	6.6	6.5	5.8	5.65	5.1	5.0	4.8	4.7
Peak No.	11	12	13	14	15	16	17	18	19	20
2 q (°) Cu	19.5	19.85	20.1	21.1	21.8	22.6	24.1	25.2	25.9	26.7
d space	4.55	4.5	4.4	4.2	4.1	3.9	3.7	3.5	3.4	3.3
Peak No.	21	22	23	24	25	26	27	28	29	30
2 q (°) Cu	28.3	30.9								
d space	3.1	2.9								

15

5. A compound according to claim 2 wherein said compound is polymorph C characterized by the following peaks in its X-ray powder diffraction pattern

Peak No.	1	2	3	4	5	6	7	8	9	10
2 q (°) Cu	6.0	8.3	10.3	11.5	12.55	13.45	16.0	16.75	17.4	17.9
d space	14.7	10.6	8.6	7.7	7.05	6.6	5.5	5.3	5.1	4.95
Peak No.	11	12	13	14	15	16	17	18	19	20
2 q (°) Cu	18.1	18.65	19.35	20.6	23.0	24.0	24.8	26.75	27.2	36.3
d space	4.9	4.75	4.6	4.3	3.9	3.7	3.6	3.3	3.3	2.5

5 6. A compound according to claim 1 wherein said compound is N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate monohydrate.

7. A pharmaceutical composition for the treatment of a hyperproliferative disorder in a mammal which comprises a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.

10 8. The pharmaceutical composition of claim 7 wherein said hyperproliferative disorder is a cancer selected from brain, lung, squamous cell, bladder, gastric, pancreatic, breast, head, neck, renal, kidney, ovarian, prostate, colorectal, oesophageal, gynecological and thyroid cancer.

9. A method of treating a hyperproliferative disorder in a mammal which comprises administering to said mammal a therapeutically effective amount of a compound according to claim 1.

15 10. The method of claim 9 wherein said method is for the treatment of a cancer selected from brain, squamous cell, bladder, gastric, pancreatic, breast, head, neck, oesophageal, prostate, colorectal, lung, renal, kidney, ovarian, gynecological and thyroid cancer.

11. A method for the treatment of a hyperproliferative disorder in a mammal which
20 comprises administering to said mammal a therapeutically effective amount of a compound according to claim 1 in combination with an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, and anti-androgens.

25

INTERNATIONAL SEARCH REPORT

Inter nal Application No

PCT/IB 99/00612

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D239/94 A61K31/505

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A A,P	WO 96 30347 A (PFIZER INC.) 3 October 1996 see page 19, line 13 - line 23; claims 1,19-21,24; example 20 & US 5 747 498 A cited in the application -----	1-8



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

16 June 1999

Date of mailing of the international search report

25/06/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hass, C

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB 99/00612

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/IB 99 00612

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Although claims 9-11 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 99/00612

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9630347 A	03-10-1996	AU 703638 B	25-03-1999
		AU 5040696 A	10-10-1996
		BR 9601200 A	06-01-1998
		CA 2216796 A	03-10-1996
		CN 1137037 A	04-12-1996
		CZ 9600931 A	12-02-1997
		EP 0817775 A	14-01-1998
		FI 973832 A	29-09-1997
		HR 960147 A	31-08-1997
		HU 9600834 A	28-05-1997
		JP 10506633 T	30-06-1998
		NO 961299 A	01-10-1996
		NZ 286263 A	24-11-1997
		PL 313541 A	14-10-1996
		SG 43262 A	17-10-1997
		SI 9600102 A	28-02-1997
		SK 38796 A	06-08-1997